Denali Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ryan J. Watts
- Full Time Employees
- 443
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 161 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Dec 8, 2017
- CIK
- 0001714899
- Website
- denalitherapeutics.com
- Similar Companies
- Business
- Denali Therapeutics Inc. (NASDAQ: DNLI) develops therapies for neurodegenerative and lysosomal storage diseases. The company focuses on programs targeting Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and mucopolysaccharidosis type IIIA (MPS IIIA), including DNL343 for ALS and frontotemporal dementia, DNL788 for ALS and Parkinson's, tividenofusp alfa for MPS IIIA, and buntanetap for Alzheimer's; it also advances discovery efforts in other rare diseases. Founded in 2015 and headquartered in South San Francisco, California, Denali operates primarily in the United States with a pipeline built on its proprietary Engineered Antibody Transport (ATLAS) and Enzyme Transport Vehicle (ETV) technologies for crossing the blood-brain barrier. Denali Therapeutics serves the biopharmaceutical industry, targeting patients with neurodegenerative disorders through clinical-stage assets and research collaborations. Its geographic operations center in the U.S., with global partnerships extending research impact. The company maintains subsidiaries like Denali Medtech Inc. for manufacturing support.
Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up